Valeant completes acquisition of Dow Pharmaceutical Sciences

Valeant develops and markets prescription and nonprescription pharmaceutical products. Valeant specializes in the neurology and dermatology therapeutic areas primarily in the US, Canada, Mexico, Brazil, Australia, and Central Europe.

Valeant plans to maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. During the year, the company made significant strides by divesting its licensing rights in Argentina, the Asia Pacific region, Western and Eastern Europe, the Middle East and Africa. Additionally, Valeant signed an exclusive worldwide partnership agreement with GSK for retigabine, its Phase III compound for the treatment of partial on-set seizures in adult patients with refractory epilepsy.

Dow Pharmaceutical Sciences researches and develops topical dermatological pharmaceutical and biotech products for external clients. It works to formulate the gel, ointment, or cream that will carry a client’s drug, assesses its effectiveness, manufactures and packages product candidates for clinical trials, and provides regulatory affairs consulting. It provides contract research services through its Solano Clinical Research division in the US and its Bioskin subsidiary in Europe. Dow Pharmaceutical Sciences also develops dermatology products on a proprietary basis.